Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0012833 (dizziness)
 9,689 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A literature review revealed that mefloquine neurotoxicity has been demonstrated at both the preclinical and clinical levels, with nausea, dizziness, sleep disturbances, anxiety and psychosis, amongst other adverse neuropsychiatric events, reported in users. Females and individuals of low body mass index (BMI) are at apparent greater risk. Mechanisms of possible neurotoxicity may include binding to neuroreceptors and cholinesterases, inhibition of sarcoendoplasmic reticulum ATPase (SERCA) and interference with cellular Ca(2+) homeostasis, accumulation in the CNS, and reductions in CNS efflux in individuals possessing certain MDR1 polymorphisms. It may be prudent to avoid mefloquine in females and low BMI individuals, and in combination with other potentially neurotoxic agents such as the artemisinin antimalarials.
 ...
PMID:Mefloquine neurotoxicity: a literature review. 1917 93

The use of mefloquine for malaria prophylaxis has been hampered by the drug's adverse effects. Foremost among the latter are neuropsychiatric adverse effects such as dizziness, vivid dreams, epilepsy and psychosis. Recent evidence from studies in mice has implicated the lack of P-glycoprotein at the blood-brain barrier as the cause of these adverse effects. The authors present the case of a 60 year-old man who was hospitalized for psychosis following ingestion of mefloquine for malaria prophylaxis. Genetic studies have found polymorphism at the MDR1 gene with genotypes 3435TT and 2677TT which underlie high levels of mefloquine in the brain.
 ...
PMID:[Polymorphism at the MDR1 locus as a cause of mefloquine-induced psychosis]. 2130 73